Salute e Benessere

Lundbeck to share pipeline data and key insights into the progression of rare…

Studying disease progression and survival is essential to understand the natural history of MSA, however currently there is limited data available.1 The TALISMAN study will help to better understand how the disease develops over time, particularly in the early MSA population, and support phase III drug development.2 Studying disease progression and survival is essential to understand the natural history of MSA, however currently there is limited data available. 1The TALISMAN study will help...
PR Newswire
08/05/2025

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 8, 2025)— Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
Nasdaq GlobeNewswire
08/05/2025

ZINZINO AB (PUBL): Share subscription due to warrants

In the option programme Zinzino's general meeting resolved on 31 May 2022, 35,000 shares have been subscribed (series 2022/2027:2). The price per share amounted to SEK 56 and in total Zinzino's equity was raised SEK 1,960,000. In the option programme Zinzino's general meeting resolved on31 May 2022, 35,000 shares have been subscribed (series 2022/2027:2). The price per share amounted toSEK 56and in total Zinzino's equity was raisedSEK 1,960,000. The total number of B shares...
PR Newswire
08/05/2025

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year…

COPENHAGEN, Denmark – May 8, 2025.The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget,...
Nasdaq GlobeNewswire
08/05/2025

Interim report Q1 2025

Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO: “ We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Growth was driven by strong innovation especially in emerging markets, and with a continued broad pull for our solutions in developed markets. Synergies are materializing as expected and we are confirming the full-year outlook. We continue to see solid demand across the...
Nasdaq GlobeNewswire
08/05/2025

Photocure ASA: Results for the first quarter of 2025

Photocure reported total group revenues of NOK 125.3 million in the first quarter of 2025 (NOK 118.0 million), and an EBITDA of NOK 1.8 million (7.9). The cash balance at the end of the period was NOK 259.5 million. Photocure reported total group revenues ofNOK 125.3 millionin the first quarter of 2025 ( NOK 118.0 million ), and an EBITDA ofNOK 1.8 million(7.9). The cash balance at the end of the period wasNOK 259.5 million. The company continued to execute on its plan to expand...
PR Newswire
08/05/2025

Zealand Pharma Announces Financial Results for the First Three Months of 2025

Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for petrelintide create strong foundation for accelerated growth.Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into...
Nasdaq GlobeNewswire
08/05/2025

Genespire announces oral presentation at the ASGCT Annual Meeting detailing…

Milan, ITALY – 8 May 2025– Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces an upcoming oral presentation showcasing critical preclinical insights into dosing for first-in-humanin vivoliver-directed immune shielded lentiviral vector (ISLV) gene therapy for methylmalonic acidemia (MMA) at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting to be held May 13-17, 2025 in New…
Nasdaq GlobeNewswire
08/05/2025

Pharming Group reports first quarter 2025 financial results and provides…

First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product's unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quarters ...
Nasdaq GlobeNewswire
08/05/2025

Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General…

Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first quarter 2025 results today.Conference call and webcast scheduled for 8 May , 2025, at 09:00 (CET). Link to webcast here .First Quarter 2025 Business UpdateHighlightsOn 3 March 2025, Zelluna ASA announced the successful completion of a business combination between...
Nasdaq GlobeNewswire
08/05/2025

Mucopolysaccharidosis Type I Market to Witness Upsurge in Growth at a CAGR of 8%…

Key Takeaways from the Mucopolysaccharidosis Type I Market Report Key Takeaways from the Mucopolysaccharidosis Type I Market Report Discover which therapies are expected to grab the major MPS I market share @Mucopolysaccharidosis Type I Market Report Mucopolysaccharidosis Type I Overview MPS I is a rare inherited lysosomal storage disorder caused by a deficiency in the enzyme alpha-L-iduronidase (IDUA), which is essential for the breakdown of glycosaminoglycans (GAGs) such...
PR Newswire
07/05/2025

Alvotech Reports Results for the First Quarter of 2025 and Provides Business…

Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in...
Nasdaq GlobeNewswire
07/05/2025

Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025

NyxoahtoReleaseFirst Quarter 2025 Financial Results on May 14, 2025Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (EuronextBrussels/Nasdaq:NYXH)(“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a...
Nasdaq GlobeNewswire
07/05/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of voting rights 04/30/2025100,290,22089,075,490For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia Sosa Navarro, Chief of Staff to the...
Nasdaq GlobeNewswire
07/05/2025

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of…

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 7, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 7, 2025 French legal announcements bulletin n°55 ( Bulletin des Annonces Légales Obligatoires ) its convening notice that the Combined Shareholders Meeting will be held on June 17, 2025, at 10:00 am...
Nasdaq GlobeNewswire
07/05/2025

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year…

ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent HighlightsCore business revenue of $8.2 million in the first quarter of 2025, an increase of 1% over the...
Nasdaq GlobeNewswire
07/05/2025

Casino Group: Additional information regarding the termination of a guarantee in…

Additional information regarding the termination of a guarantee in favor of GPA The accelerated safeguard plan of Casino Guichard-Perrachon approved by the Paris Commercial Court on February 26, 2024, has terminated the uncapped guarantee granted by Casino for the benefit of Companiha Brasileria de Distribuiçao (GPA). This guarantee had provided for an indemnification undertaking by Casino in favor of GPA for any losses that might result from the implementation of the amortization...
Nasdaq GlobeNewswire
07/05/2025

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium…

Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an additional purchase order for 80,000 units from Pharmalink for its Sky Premium Life products in the United Arab Emirates...
Nasdaq GlobeNewswire
07/05/2025

New Executive Management Board at Bender - the world's leading provider of…

- Picture is available at AP - - Picture is available atAP - As of1 May 2025Bender appoints a new Executive Board – a significant step marking the strategic realignment of the company.Michael Breueras Chief Executive Officer (CEO) andNicole Benderas Chief Financial Officer (CFO) are setting the course for the future development of the company. „On behalf of Bender and the Supervisory Board, I am excited to welcomeMichael BreuerandNicole Benderas the new Executive...
PR Newswire
07/05/2025

Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST…

SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEMGhent, Belgium, 7 May 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a second subscription request notice in accordance with the terms of the share subscription facility…
Nasdaq GlobeNewswire
07/05/2025

VALNEVA Declaration of shares and voting rights: April 30, 2025

VALNEVADeclaration of shares and voting rightsApril 30, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: May 7, 2025 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the change ...
Nasdaq GlobeNewswire
07/05/2025

Valneva Provides Update Following European Medicines Agency Announcement on Use…

Saint Herblain (France), May, 07 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva's single-dose live attenuated chikungunya vaccine IXCHIQ ®based on reports of serious adverse events (SAEs) in elderly people. As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current...
Nasdaq GlobeNewswire
07/05/2025

Continued growth in revenue and operating profit

Trading statement for Q3 2024/25 (1 January - 31 March 2025) Continued growth in revenue and operating profit Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9 million in the year-earlier period. Growth was driven primarily by sales of products related to the NC platform, reflecting increased activity levels for customers with ongoing clinical trials and approved therapies. The Q3 performance reflected continued growth in sales of both instruments,...
Nasdaq GlobeNewswire
07/05/2025

Single Cell Analysis Market worth US$7.56 billion by 2030 with 14.7% CAGR |…

Browse in-depth TOC on "Single Cell Analysis Market" Browse in-depth TOC on "Single Cell Analysis Market" 721 - Tables 66 - Figures 517 - Pages By Based on product,the single-cell analysis market is segmented into consumables and instruments. The consumables segment is further divided into reagents, assay kits, beads, microplates, and other consumables. The instruments segment is further segmented into next-generation sequencing, microscopy, flow cytometry, polymerase…
PR Newswire
07/05/2025
Altri  Comunicati